Feasibility of Matching-Adjusted Indirect Comparison (MAIC) of Omalizumab (OMA) vs. Mepolizumab (Mepo) in Moderate-to-Severe Asthma
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1170
https://www.valueinhealthjournal.com/article/S1098-3015(16)32536-0/fulltext
Title :
Feasibility of Matching-Adjusted Indirect Comparison (MAIC) of Omalizumab (OMA) vs. Mepolizumab (Mepo) in Moderate-to-Severe Asthma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32536-0&doi=10.1016/j.jval.2016.09.1170
First page :
A549
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1098